Physiological Effects of Drugs
44
5
9
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.8%
3 terminated out of 44 trials
88.0%
+1.5% vs benchmark
36%
16 trials in Phase 3/4
41%
9 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (44)
Natural History of Depression, Bipolar Disorder and Suicide Risk
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Antidiabetic Drugs for Steatotic Liver Disease
Behavior Brain Responses
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder